当連結累計年度のわが国経済は、政府・日銀による経済対策および金融政策により、緩やかな景気回復基調で推移し、雇用・所得環境も改善傾向が見られた。一方、個人消費は、消費税率引き上げに伴う駆け込み需要とその反動、夏場の天候不順の影響などにより、回復の遅れが見られた。

 

当社グループは、長期経営指針実現の第一ステップである2012-2014年度グループ中期経営計画の最終年度を迎え、重点テーマ「収益性向上と飛躍に向けた戦略投資」に基づき、「既存事業の強化・拡大」「成長事業の育成」「収益性の向上」を引き続き進めた。 食品セグメントでは、原材料調達コストやエネルギーコストの大幅な上昇に対処した。乳製品、菓子、健康栄養の各事業で主力製品の販売を拡大しプロダクトミックスを改善し、事業構造改革と徹底したコストダウンを行った。 医薬品セグメントでは、「スペシャリティ&ジェネリック」戦略を推進、医療用医薬品の普及を強化し、国内外の生産拠点を活用して原価を低減した。

  

この結果、当期売上高は11,60080百万円(前期比2.5%増)、営業利益は62540百万円(同35.8%増)、経常利益は55500百万円(同35.8%増)、当期純利益は29800百万円(同57.5%増)となった。

 

中期経営計画策定時の目標である売上高12,500億円、営業利益500億円、ROE 7%に対し、売上高は、食品セグメントの低採算事業の見直しなどにより目標達成しませんでしたが、営業利益とROE目標は、食品・医薬品の両セグメントでの構造改革が奏功し、目標を大幅に上回った。

During the cumulative consolidated fiscal year, the Japanese economy showed signs of improvement as employment and income indicators trended higher thanks to mild economic recovery driven by government and Bank of Japan economic measures and monetary policies. On the other hand, recovery was slowed due to factors including the impact of last-minute demand ahead of consumption tax rate hike, the adverse reaction following the take rate hike, and poor weather during the summer months.

 

This year is the final year of our Medium-Term Business Plan for fiscal years 2012-2014 and represents the first step towards achieving our long-term corporate strategy. Committed to our core theme of achieving higher profitability and conducting strategic investments for future growth, our Group has focused on “strengthening and expanding existing businesses,” “fostering growth businesses,” and “improving profitability”. In the food segment, we implemented measures to address sharp increases in raw material and energy costs. We increased sales of mainstay products in our Dairy, Confectioneries, and Health & Nutritionals businesses, and improved our product structure. We also implemented structural reforms and cost reduction measures. In the pharmaceuticals segment, we advanced our Specialty & Generics Strategy and increased market share for pharmaceutical products while using our international production network to reduce costs.

 

As a result, the Group recorded net sales of 1,160,080 million yen (YoY increase of 2.5%), operating income of 62,540 million yen (YoY increase of 35.8%), recurring income of 55,500 million yen (YoY increase of 37.1%), and net profit of 29,800 million yen (YoY increase of 57.5%).

 

The initial goals outlined in our Medium-Term Management Plan were net sales of 1,250,000 million yen, operating income of 50,000 million yen, and an ROE of 7%. While net sales fell short of goals due to the elimination of unprofitable operations in the food segment, operating income and ROE both greatly exceeded goals thanks to structural reforms in the food and pharmaceutical segments.